Positron Emission Tomography clinical trials
12 indexed studies · 8 currently recruiting
- RecruitingPHASE2
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
This study looks at combining nivolumab, an immunotherapy drug, with chemotherapy and then radiation for young people with nasopharyngeal cancer. Researchers want to see if this new treatment can fight the cancer effectively, understand its side effects, and potentially reduce radiation for children.
For: Stage II Nasopharyngeal Carcinoma AJCC v8 · Stage III Nasopharyngeal Carcinoma AJCC v8 · Stage IV Nasopharyngeal Carcinoma AJCC v8United States · Canada · New Zealand - Active not recruitingPHASE3
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
This study compares two immunotherapy drugs (nivolumab or brentuximab vedotin) when used with chemotherapy for newly diagnosed, advanced Hodgkin lymphoma. It aims to see which combination works best at shrinking the cancer and keeping it away.
For: Ann Arbor Stage III Hodgkin Lymphoma · Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma · Ann Arbor Stage III Mixed Cellularity Classic Hodgkin LymphomaUnited States · Canada · Puerto Rico - RecruitingPHASE2
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
This study looks at adding a new drug, relatlimab, to current treatments for nasopharyngeal cancer that has come back or spread. The aim is to see if this addition can help keep the cancer from growing or spreading for longer.
For: Metastatic Nasopharyngeal Carcinoma · Recurrent Nasopharyngeal Carcinoma · Stage IV Nasopharyngeal Carcinoma AJCC v8United States · Australia · Canada - RecruitingPHASE1
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
This study is testing a new combination of treatments for advanced pancreatic neuroendocrine tumours. We want to see if adding sunitinib malate to lutetium Lu 177 dotatate is safe and effective. This research aims to find better ways to fight these specific cancers.
For: Metastatic Pancreatic Neuroendocrine Tumor · Pancreatic Neoplasm · Stage III Pancreatic Neuroendocrine Tumor AJCC v8United States · Canada - Active not recruitingPHASE2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
This study looks at combining a drug called relugolix with usual radiation therapy for advanced prostate cancer that has spread to limited other areas. It aims to see if this combination helps stop the cancer from spreading further compared to radiation alone.
For: Oligometastatic Prostate Carcinoma · Prostate Adenocarcinoma · Prostate Ductal AdenocarcinomaUnited States · Canada - RecruitingPHASE2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
This study helps doctors find the best treatments for people with certain blood cancers like leukaemia. It uses special tests on blood and bone marrow to match patients with personalised treatments or standard care, aiming to improve how cancer treatments are chosen.
For: Acute Myeloid Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · Acute Myeloid Leukemia Post Cytotoxic TherapyUnited States · Canada · Puerto Rico - RecruitingPHASE3
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
This study looks at the best way to treat a rare childhood lung cancer called Pleuropulmonary Blastoma (PPB). For Type I PPB, it compares surgery alone to surgery with chemotherapy. For Types II and III PPB, it adds a new drug, Topotecan, to standard treatment.
For: Pleuropulmonary BlastomaUnited States · Canada - Active not recruitingPHASE3
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
This study looks at new ways to treat a type of cancer called rhabdomyosarcoma, which can be aggressive. We're testing if adding a drug called vinorelbine to standard treatment, and then using a 'maintenance' therapy, helps stop the cancer from coming back.
For: Alveolar Rhabdomyosarcoma · Botryoid-Type Embryonal Rhabdomyosarcoma · Embryonal RhabdomyosarcomaUnited States · Australia · Canada - RecruitingPHASE3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
This study compares two ways to give radiation therapy for high-risk prostate cancer. One uses fewer, stronger treatments (SBRT), and the other is the usual longer course. We want to see if the shorter treatment works just as well to stop the cancer from coming back.
For: Prostate Adenocarcinoma · Stage III Prostate Cancer AJCC v8 · Stage IVA Prostate Cancer AJCC v8United States · Canada · Hong Kong - RecruitingPHASE3
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
This study is giving children and young adults with a type of soft tissue cancer called rhabdomyosarcoma new chemotherapy. It aims to see if less harsh treatment works for those with very low-risk cancer, and if standard treatment works well for others, while also studying patients with specific genetic changes.
For: Embryonal Rhabdomyosarcoma · Fusion-Negative Alveolar Rhabdomyosarcoma · Spindle Cell/Sclerosing RhabdomyosarcomaUnited States · Australia · Canada - RecruitingPHASE2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
This study looks at new ways to treat a rare type of skin cancer called mucosal melanoma, found inside the body. It tests if a drug called nivolumab, alone or with another drug called cabozantinib, can stop the cancer from coming back after surgery or help those where surgery wasn't enough.
For: Anal Melanoma · Bladder Melanoma · Cervical MelanomaUnited States · Canada - Active not recruitingPHASE2
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
This study looks at combining two cancer drugs, tuvusertib and avelumab, for people with advanced Merkel cell skin cancer that hasn't responded to previous treatment. It aims to see if the combination works better than tuvusertib alone to stop the cancer from getting worse.
For: Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 · Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 · Locally Advanced Merkel Cell CarcinomaUnited States · Canada